Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Ranked by Industry as Best U.S. Life Sciences Firm

November 12, 2004

WASHINGTON, D.C., November 12, 2004 - Covington & Burling announced today it has been ranked as the number one life sciences regulatory law firm worldwide and the best U.S. law firm overall that advises the life sciences sector. The Life Sciences Super League law firm rankings, published in Global Counsel magazine's November 2004 issue, are based on an independent survey of industry and private practice lawyers.  The overall life sciences rankings assess a broad range of legal services, including corporate partnering, IP, competition and antitrust, product liability, regulatory and commercial law.

The firm has consistently been one of the leading law firms in the area of life sciences and this is the second year running that the firm has been ranked as the number one life sciences regulatory law firm. Over 145 firm lawyers, drawn from different legal disciplines, are experienced advisers to the life sciences industry.

"This is a tribute to our lawyers' depth of industry knowledge and expertise in the life sciences field and their ability to achieve our clients' goals," said Stuart Stock, the chair of the firm's management committee. "It's great to have our clients' vote of confidence."

Covington recently further strengthened its European Life Sciences team by adding to the partnership  Anne Ware, a leading U.K. product liability lawyer who has more than 20 years experience in advising pharmaceutical companies.

Share this article: